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The renal distal convoluted tubule (DCT) has an essential role
in maintaining systemic magnesium (Mg2þ ) concentration.
The DCT is the final determinant of plasma Mg2þ levels, as
the more distal nephron segments are largely impermeable
to Mg2þ. In the past decade, positional candidate strategies
in families with inherited forms of hypomagnesemia have led
to the identification of genes involved in Mg2þ handling.
A large fraction of this resides in the DCT, namely, (i) the
transient receptor potential channel melastatin subtype 6
(TRPM6), a divalent cation-permeable channel located at the
luminal membrane of the DCT, facilitates Mg2þ entry from
the pro-urine into the cell; (ii) the epidermal growth factor is
a novel hormone regulating active Mg2þ transport through
TRPM6; (iii) the voltage-gated Kþ channel, Kv1.1, establishes
a favorable luminal membrane potential for TRPM6-mediated
Mg2þ transport; (iv) the Naþ/Kþ-ATPase c-subunit (c-Naþ/Kþ
-ATPase) was identified as mutated protein in a family with
isolated dominant hypomagnesemia. The molecular
mechanism by which c-Naþ/Kþ-ATPase is involved in DCT
Mg2þ handling remains unknown; (v) a high percentage of
patients with mutations in the renal transcription factor
HNF1B (hepatocyte nuclear factor 1 homeobox B) gene
develop hypomagnesemia; and (vi) Gitelman and EAST/
SeSAME syndrome patients suffer from a similar tubulopathy
due to mutations in NCC (NaCl cotransporter) and Kir4.1,
respectively. In these patients, decreased expression of
TRPM6 is proposed to cause hypomagnesemia. Insights into
the molecular mechanisms of the identified genes, as well as
the identification of novel genes, will further improve our
knowledge about renal Mg2þ handling.
Kidney International (2010) 77, 17–22; doi:10.1038/ki.2009.358;
published online 7 October 2009
KEYWORDS: epidermal growth factor; epithelial; genetic renal disease;
tubular epithelium
Magnesium (Mg2þ ) is a versatile electrolyte shown to be
involved in many cellular processes. It functions as a cofactor
in the energy metabolism, nucleotide and protein synthesis,
and as a regulator of sodium (Naþ ), potassium (Kþ ), and
calcium (Ca2þ ) channels. To maintain these cellular func-
tions, plasma Mg2þ levels have to be kept within a narrow
range (0.70–1.1 mmol/l). A representative study showed that
a surprisingly high percentage of hospitalized patients (acute
26.1% and chronic 3.5%) are diagnosed with hypomagnese-
mia.1 Hypomagnesemia is observed under various conditions
(i) by use of drugs such as the immunosuppressive agent,
cyclosporine,2 anti-acidic drugs like omeprazole and esome-
prazole,3,4 and anticancer drugs like cetuximab5,6 and
cisplatin;7 (ii) by inherited forms; and (iii) secondary to
other medical conditions like diabetes mellitus type II.
Symptoms of hypomagnesemia include muscle cramps,
tremors, tetany, a short QT interval on the electrocardio-
graphy, and in some instances, cardiac arrhythmia. Persistent
hypomagnesemia can eventually cause death. Patients suffer-
ing from severe hypomagnesemia are often supplemented
with Mg2þ . A high dose of Mg2þ , however, can have serious
adverse effects such as diarrhea and abdominal cramping.
Furthermore, magnesium salts are often given in case of
severe asthma attacks8 and to treat pre-eclampsia in
pregnant women.9 The molecular mechanism by which
Mg2þ improves the pathological conditions is at this
point unknown.
Three organs determine the plasma Mg2þ level, namely,
the intestine by which Mg2þ is taken up from the food,
bones, which store and release Mg2þ , and the kidney, which
determines the excretion of Mg2þ . The intake of Mg2þ is
B300–350 mg/day of which 40–60% is absorbed by the
intestine.10 Mg2þ absorption takes place along the intestinal
tract by passive para- or active transcellular pathways.11 With
normal dietary content, Mg2þ is most efficiently absorbed in
the distal part of the small bowel in a passive manner. When
Mg2þ intake is low, the Mg2þ absorption is increased
through active transport systems in the large intestines.11,12
The highest percentage (50–60%) of total body Mg2þ is
stored in the skeleton. It is hypothesized that bone serves as a
buffer for plasma Mg2þ . At this point, little is known about
the mechanisms by which Mg2þ is stored in bone by
osteoblasts and released by osteoclasts.13,14 The kidneys are
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involved in the regulation and fine-tuning of the final Mg2þ
concentration in plasma. Each day, B2500 mg of Mg2þ is
filtered by the glomeruli of which 90–95% is reabsorbed along
the nephrons (Figure 1). The highest level of reabsorption
occurs in the proximal tubules and the thick ascending limbs
of Henle’s loop (TAL) in a passive paracellular manner
(10–30% and 40–70%, respectively) (Figure 1). The mechan-
isms that manage Mg2þ transport in the proximal tubules
are unknown, whereas in the TAL, Mg2þ reabsorption is
facilitated by the tight junction proteins, claudin-1615 and
claudin-1916 (Figure 1). Mutations in claudin-16 and
claudin-19 are causative for familial hypomagnesemia with
hypercalciuria and nephrocalcinosis (FHHNC; OMIM
248250). A recent study showed that the interaction between
tight junction proteins, claudin-16 and claudin-19, forms a
specific cation-permeable channel. FHHNC mutations have
been shown to disrupt the cation-selective properties of
the claudin-16 and claudin-19 channels. This presumably
disrupts the lumen positive potential that generates passive
paracellular transport of Mg2þ .17 The final 5–10% of the
filtered load is reabsorbed by the distal convoluted tubule
(DCT) (Figure 1), which consists of two subsegments,
namely, DCT1 and DCT2. The DCT1 segment determines
the final Mg2þ concentration, as the more distal parts of
the tubule are largely impermeable to Mg2þ . In DCT1,
Mg2þ reabsorption occurs in an active transcellular manner
through previously unknown mechanisms (Figure 1). In
recent years, positional candidate approaches in families with
monogenetic forms of hypomagnesemia have allowed the
identification of new genes and derived proteins involved in
active renal Mg2þ handling. This review provides an
overview of the most recent findings.
PATHOPHYSIOLOGY OF MONOGENETIC DISORDERS IN
HYPOMAGNESEMIA
Transient receptor potential channel melastatin member 6
Walder et al. reported three consanguineous kindreds
suffering from hypomagnesemia and secondary hypocalce-
mia (HSH; OMIM 602014; Table 1). The phenotype
manifested 2–8 weeks after birth and consisted of neurolo-
gical symptoms such as tetany, muscle spasms, and seizures.
These patients display low plasma Mg2þ levels
(0.1–0.4 mmol/l) that are caused by defective intestinal and
renal absorption of Mg2þ .18 The low plasma Ca2þ levels are
secondary, likely due to parathyroid failure caused by
hypomagnesemia (Table 1). Hypomagnesemia blocks the
secretion of parathyroid, hence resulting in decreased
reabsorption of Ca2þ by the kidney.19 A whole-genome
scanning approach showed linkage to chromosome 9p22.18
In the following years, two groups independently identi-
fied new HSH families that were used to narrow down the
critical region by use of haplotyping analysis. Subsequent
screening for candidate genes in the mapped region resulted
in the identification of homozygous and compound hetero-
zygous mutations in the transient receptor potential channel
melastatin member 6 (TRPM6; OMIM 607009) gene
(Table 1).20,21 By use of immunohistochemistry, the TRPM6
protein was shown to localize to the luminal membrane of
DCT cells and the brush-border membrane of the intestine
(Figure 1).22 The closest relative of TRPM6 is TRPM7, which
is ubiquitously expressed. A striking feature of both channels
is the a-kinase domain, which is located at the intracellu-
lar carboxy (C)-terminus. Functional analysis identified
TRPM6 as a Mg2þ - and Ca2þ -permeable channel, although
the affinity for the latter ion is five times lower (Figure 2).22
The a-kinase domain is proposed to function as a sensor of
the intracellular Mg2þ concentration. As a consequence, the
Mg2þ influx through TRPM6 is regulated, preventing intra-
cellular Mg2þ overload. Recently, a receptor for activated
C-kinase 1 and repressor of estrogen receptor activity were
identified as the TRPM6 a-kinase domain-interacting
proteins. Receptor for activated C-kinase 1 and repressor of
estrogen receptor activity were shown to function as a
dynamic switch controlling TRPM6 channel activity through
the a-kinase domain. Moreover, TRPM6 is inhibited on
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Figure 1 |Renal Mg2þ reabsorption. The glomerulus filters
Mg2þ, of which 90–95% is subsequently reabsorbed along the
nephron. Approximately 10–30% of the Mg2þ is reabsorbed by
the proximal tubule in a passive manner. The highest level is
reabsorbed by the thick ascending loop of Henle (TAL) (40–70%).
In this part of the nephron, Mg2þ transport is facilitated in a
passive paracellular manner by tight junction proteins claudin-16
and claudin-19. Only 5–10% of the filtered load is reabsorbed in
the distal convoluted tubule (DCT); however, this segment
determines the final Mg2þ concentration through active
transcellular transport. CD, collecting duct; CNT, connecting
tubule; PT, proximal tubule.
18 Kidney International (2010) 77, 17–22
min i rev iew B Glaudemans et al.: Molecular players facilitating Mg2þ reabsorption
interaction of adenosine-50-triphosphate (ATP) with a
specific motif in the a-kinase domain. A recent review gives
an overview of the molecular regulation of TRPM6.23
Epidermal growth factor
Recently, the epidermal growth factor (EGF) was identified as
a novel magnesiotropic hormone.24 Geven et al.25 reported
two sisters with autosomal recessive isolated renal hypomag-
nesemia caused by consanguineous mating (HOMG4; OMIM
611718; Table 1). The patients suffer from epileptic seizures
and mild mental retardation. By use of a whole-genome
linkage analysis and a subsequent candidate gene approach,
EGF (OMIM 131530) was shown to be the affected gene in
these patients.24 The EGF gene codes for pro-EGF, a small
peptide hormone expressed in several organs, including
gastrointestinal tract, respiratory tract, and kidney. In rat
kidney, pro-EGF was shown to localize primarily in DCT24,26
(Figure 1). Pro-EGF is a type-1 membrane protein that is
sorted and subsequently inserted into the luminal and
basolateral membrane of the epithelial cells.27 It consists of
a small intracellular C-terminal tail, one trans-membrane
domain, and a large extracellular amino (N)-terminal
segment. On membrane insertion, pro-EGF is processed by
unknown proteases into a functional EGF peptide
hormone, which activates EGF receptors (EGFRs) on the
basolateral membrane (Figure 2). As a result, EGF
stimulates the trafficking of TRPM6 channels to the luminal
membrane, increasing the reabsorption of Mg2þ through
TRPM6 (Figure 2).28 The function of EGF at the luminal
membrane is unknown, which is particularly interesting as
EGFRs are absent at the luminal membrane of DCT.29
Patients suffering from metastatic colorectal cancer
are often treated with antibodies raised against the EGFR,
such as cetuximab. Strikingly, EGFR monoclonal
antibody therapy has been shown to result in hypomagne-
semia in a significant number of patients.5,6 The mutation,
observed in the family with isolated renal hypomagnesemia,
disrupts the basolateral-sorting motif in pro-EGF. For
that reason, pro-EGF can likely not travel to the basolateral
membrane leading to impaired stimulation of the EGFR
and subsequent reduced Mg2þ transport by TRPM6
(Figure 2).
Table 1 | Genes associated with inherited forms of hypomagnesemia resulting in impaired Mg2+ reabsorption in the DCT
Phenotype
Blood Urine
Gene Protein Mg2+ Ca2+ K+ Na+ pH Mg2+ Ca2+ K+ Na+ Other Reference
TRPM6 TRPM6 kk k 2 2 2 2a 2 n.d. n.d. Mental retardation; epilepsy Walder et al.18;
Schlingmann et al.20;
Walder et al.21
EGF EGF kk 2 2 2 2 2a 2 n.d. n.d. Mental retardation Groenestege et al.24
KCNA1 Kv1.1 kk 2 2 2 n.d. 2a 2 n.d. n.d. Episodic ataxia 1; myokymia Glaudemans et al.30
FXYD2 gNa+/K+-ATPase kk 2 2 2 2 mm kk n.d. n.d. None Meij et al.34
HNF-1b HNF1B k 2 n.d. n.d. n.d. m k n.d. n.d. Cystic kidneys; diabetes mellitus Adalat et al.38
Slc12a3 NCC k 2 k 2 m m kk m m Increased bone mineral density Simon et al.39
KCNJ10 Kir4.1 k 2 k 2 m m kk m m Epilepsy; ataxia; sensorineural
deafness
Scholl et al.45;
Bockenhauer et al.44
k, low; m, high; 2, normal; n.d., not defined; DCT, distal convoluted tubule; EGF, epidermal growth factor; HNF1B, hepatocyte nuclear factor 1 homeobox B; NCC, NaCl
cotransporter; TRPM6, transient receptor potential ion channel member 6.
Gene name, plasma electrolytes, urinary electrolytes, and other phenotypic characteristics of proteins affected in patients suffering from hypomagnesemia.
aLow plasma Mg2+ levels and normal urinary Mg2+ excretion indicates a renal Mg2+ reabsorption defect.
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Figure 2 | Electrolyte handling in the distal convoluted tubule
(DCT). Mutations in these proteins cause hypomagnesemia, in some
cases associated with other phenotypes (Table 1). Transient receptor
potential ion channel member 6 (TRPM6) is located at the luminal
membrane of the DCT, in which it facilitates transport of Mg2þ from
the pro-urine into the cell. Mg2þ reabsorption is primarily driven by
the luminal membrane potential established by the voltage-gated
Kþ channel, Kv1.1. The epidermal growth factor (EGF) was
discovered as the first hormone to regulate active Mg2þ
reabsorption through TRPM6. The Naþ/Kþ-ATPase, situated in the
basolateral membrane, provides the sodium (Naþ ) gradient that is
used by NaCl cotransporter (NCC) to facilitate cotransport of
Naþ and chloride (Cl) from the pro-urine into the cytoplasm.
Potassium (Kþ) is supplied to the Naþ/Kþ-ATPase through Kir4.1,
whereas the efflux of Cl to the interstitium occurs through chloride
channel subunit b (ClC-Kb). The g-subunit of the Naþ/Kþ-ATPase
may regulate the function of a and/or b subunits; however, the exact
function is unknown. Transcription factor HNF1B (hepatocyte nuclear
factor 1 homeobox B) is proposed to regulate the expression of the
g-subunit of the Naþ/Kþ-ATPase. EGFR, EGF receptor.
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Kv1.1
Another gene presumed to regulate Mg2þ handling through
TRPM6 is KCNA1. Recently, a mutation in the KCNA1 gene,
coding for the voltage-gated Kþ channel Kv1.1 (OMIM
176260), was shown to be causative for autosomal-dominant
hypomagnesemia (0.28–0.37 mmol/l) in a large Brazilian
family (Table 1).30 The phenotype detectable from infancy
consisted of recurrent muscle cramps, tetany, tremor, muscle
weakness, cerebellar atrophy, and myokymia. Kv1.1 coloca-
lizes with TRPM6 along the luminal membrane of the DCT
(Figure 1). Functional Kv1.1 channels are composed of four
subunits that form homo- or heterotetramers in assembly
with other Kv channel subunits. Functional analysis showed
that the mutation results in a non-functional channel with a
dominant-negative effect on wild-type channel function, in
line with the pattern of inheritance observed in the family.
The Mg2þ influx through TRPM6 is energized by the local
electrochemical gradient. Importantly, the DCT cell lacks a
substantial chemical gradient for Mg2þ . The Mg2þ con-
centration in the pro-urine is likely around 1.1 mmol/l,
whereas the free intracellular Mg2þ concentration has been
estimated to be 0.5–1.0 mmol/l (Figure 2).31 The luminal
membrane potential in the DCT is approximately 70 mV,32
favouring luminal Mg2þ influx (Figure 2). Thus, the
movement of Mg2þ into the DCT cell seems mainly driven
by the electrical gradient. The renal outer medullary
potassium channel has been proposed to generate the
luminal membrane potential through Kþ efflux. Never-
theless, immunolocalization studies show specific renal outer
medullary potassium channel staining in the TAL and
connecting tubule, but not in the DCT.33 Alternatively,
Kv1.1 has been identified as luminal Kþ channel in DCT that
establishes a favorable luminal membrane potential to
control TRPM6-mediated Mg2þ reabsorption (Figure 2).
Consequently, mutation of Kv1.1 leads to impairment of
renal Mg2þ handling.30 Finally, previously identified KCNA1
mutations in a mixed phenotype of episodic ataxia 1,
myokymia, and epilepsy (OMIM 160120), were not yet
associated with hypomagnesemia. It would therefore be of
interest to investigate the plasma Mg2þ levels in this latter
group of patients with KCNA1 mutations.
c-Subunit of the Naþ/Kþ-ATPase
Another identified gene proposed to have a role in Mg2þ
homeostasis is FXYD2 (FXYD2; OMIM 601814). FXYD2
encodes the g-subunit of the basolateral Naþ /Kþ -ATPase (g)
and is mutated in patients with autosomal-dominant renal
hypomagnesemia associated with hypocalciuria (IDH;
OMIM 154020; Table 1). The hypomagnesemia in these
patients can be as low as 0.40 mmol/l resulting in convul-
sions.34 The FXYD2 gene encodes two splice variants, namely
ga and gb, which locate to different segments of the nephron.
Both variants are expressed along the nephron and colocalize
in the proximal tubules and the TAL. Splice variant ga is
specifically expressed in the macula densa and the collecting
duct, whereas gb localizes to the basolateral membrane of the
DCT and the connecting tubule region (Figure 1).35 Im-
munolocalization studies of gb-expressing cells showed
normal membrane localization of wild-type gb, whereas
mutant gb membrane trafficking was impaired.36 Yet, the
exact molecular mechanism by which g regulates Mg2þ
handling in the DCT remains elusive. It has been suggested
that g facilitates the basolateral extrusion of Mg2þ in renal
epithelial cells.37 Others suggest a role for g in the regulation
of other transport mechanisms that localize to the basolateral
membrane such as the Naþ /Kþ -ATPase (Figure 2), Kir4.1,
or the basolateral extrusion mechanism for Mg2þ .
Hepatocyte nuclear factor 1 homeobox B
Further evidence for an instrumental role of the g-subunit in
Mg2þ reabsorption was provide by a recent study showing
that the transcription factor hepatocyte nuclear factor 1
homeobox B (HNF1B) was linked to the regulation of the
FXYD2 gene. Hypomagnesemia, hypermagnesuria, and
hypocalciuria were observed in 44% of the HNF1B mutation
carriers (OMIM 137920). Analysis of the FXYD2 promoter
region resulted in the identification of a highly conserved
HNF1B recognition site. By use of subsequent luciferase
reporter assays, the authors showed the control of FXYD2
gene expression by HNF1B.38 Future studies should confirm
the role of HNF1B in the regulation of FXYD2 and possibly
other components of the molecular machinery involved in
renal Mg2þ handling (Figure 2).
NaCl cotransporter
Gitelman syndrome (GS) is an autosomal recessive disorder
characterized by hypokalemic metabolic alkalosis in con-
junction with significant hypomagnesemia and hypocalciuria
(OMIM 263800; Table 1). GS is one of the most frequently
occurring renal tubular disorders with a prevalence of
1:40,000 in the Caucasian population (heterozygotes 1:100).
Periods of muscle weakness and tetany are commonly
observed in patients with GS. The underlying cause for the
Gitelman phenotype are homo- or compound heterozygous
mutations or deletions in the solute carrier family 12,
member 3 (Slc12a3) gene that codes for the thiazide-sensitive
NaCl cotransporter (NCC; OMIM 600968).39 NCC is
expressed at the luminal membrane of DCT, in which it
facilitates cotransport of Naþ and Cl from the pro-urine
into the cell (Figure 2). Inactivating mutations in NCC cause
renal NaCl wasting and activation of the renin–angiotensi-
n–aldosterone system. This likely leads to hypokalemic
alkalosis as a result of increased Naþ load and compensatory
reabsorption in the connecting tubule/collecting duct region
through the epithelial Naþ channel, presumably in exchange
for Kþ through the renal outer medullary potassium
channel. The electrolyte disturbances in GS resemble the
effect caused by chronic thiazide administration, a specific
blocker of NCC. The disturbances in mineral metabolism
observed in GS, are secondary to mutations in NCC.
Increased passive reabsorption of Ca2þ by the proximal
tubules and decreased expression of TRPM6 in the DCT are
20 Kidney International (2010) 77, 17–22
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proposed to explain the hypocalciuria and hypomagnesemia,
respectively (Figure 1 and 2).40 It has been suggested
that increased aldosterone levels observed in GS patients
may be the causative reason for the decreased TRPM6
expression.40
After transport through the NCC, Naþ is extruded across
the basolateral membrane through the Naþ /Kþ -ATPase,
whereas Cl transport occurs through the chloride channel,
subunit b (ClC-Kb) (Figure 2). Interestingly, mutations in
the CLCNKB gene, coding for ClC-Kb, can cause a
phenotypic spectrum from antenatal Bartter syndrome to a
more GS-like phenotype with hypomagnesemia and
hypocalcaemia. Bartter syndrome is a renal autosomal
recessive disorder, defined by hypokalemic metabolic alka-
losis, which is similar to the GS phenotype. A review by
Hebert41 provides a clear overview on the Bartter syndrome
characteristics. Immunohistochemistry revealed ClC-Kb
expression in the basolateral membrane of both the TAL
and the DCT (Figure 1).42 The patient phenotype as well as
the expression pattern suggests that ClC-Kb facilitates
basolateral Cl transport in both the TAL and the DCT
(Figure 2).43
Kir4.1
Recently, two groups independently revealed a new syndrome
closely resembling the GS phenotype. The first study
presented two non-related consanguineous families suffering
from a disorder characterized by epilepsy, ataxia, sensor-
ineurol deafness, and tubulopathy (EAST (also referred to as
SeSAME); OMIM 612780; Table 1),44 whereas the second
study described four kindreds with similar clinical findings.45
Both studies revealed a mutation within the KCNJ10 gene as
the underlying cause of the syndrome in these patients. The
KCNJ10 gene encodes the Kþ channel Kir4.1 that is
expressed in brain, ear, and kidney, in line with the
phenotype observed in these patients. Current clamp
experiments in Xenopus laevis oocytes injected with Kir4.1
cRNA showed decreased function of Kir4.1 EAST syndrome
mutants compared with wild-type Kir4.1. The renal pheno-
type of EAST syndrome is similar to the GS phenotype and
consists of polyuria, hypokalemic metabolic alkalosis,
hypomagnesemia, and hypocalciuria (Table 1). Interestingly,
polyuria is a phenotypic characteristic of Bartter syndrome
that is not observed in GS, which is in line with the
hypercalciuria observed in the Bartter patients.46 Kir4.1
knockout mice die within several days, most likely as a result
of seizures.47,48 In line with the human clinical findings,
phenotypic characteristics of these mice include deafness,
ataxia, polyuria, hypokalemic metabolic alkalosis, hypomag-
nesemia, and hypocalciuria.44,48,49 In the kidney, Kir4.1 is
expressed at the basolateral membrane of distal tubular
epithelia,50 together with the Naþ /Kþ -ATPase (Figure 1).
The Naþ /Kþ -ATPase facilitates transport of Naþ to the
interstitium and Kþ to the intracellular compartment against
their respective chemical gradients, generating a driving
force for luminal NaCl influx through NCC and basolateral
Cl transport through ClC-Kb. Kir4.1 is suggested to recycle
Kþ into the interstitium to allow a sufficient supply of Kþ
for optimal Naþ /K ATPase activity (Figure 2). Importantly,
as reflected by the high density of mitochondria in the DCT,
the Naþ /Kþ -ATPase activity is here the highest of all
nephron segments.51 In DCT, a high Naþ /K ATPase activity
may be necessary to support the substantial transport of NaCl
and Mg2þ .
CONCLUSIONS
In the past decade, the identification of disease genes by use
of families with inherited forms of hypomagnesemia has
pointed toward a prominent function of the DCT in overall
Mg2þ handling. TRPM6 was identified as a likely candidate
for influx of Mg2þ across the luminal membrane, whereas
receptor for activated C-kinase 1 and repressor of estrogen
receptor activity were shown to regulate TRPM6 function
through the C-terminal a-kinase domain. Nevertheless,
insights into TRPM6 function and regulation are incomplete.
Knockout animals are often used to investigate protein
function, but unfortunately, TRPM6 knockout mice are not
viable.52 Alternatively, conditional TRPM6 knockout animals
should allow the investigation of the renal and/or intestinal
function of TRPM6 in detail. EGF was identified as a novel
magnesiotropic hormone by its stimulatory effect on TRPM6
activity (Figure 2). EGFR blockers, such as cetuximab, are
often used to treat patients suffering from head, neck, and
colorectal cancer. Interestingly, a high incidence of sympto-
matic hypomagnesemia is observed among patients who
receive cetuximab. It is a future challenge to produce EGFR-
targetted antibodies, which can be used to treat cancer
patients without causing the symptoms of hypomagnesemia.
The Kv1.1 channel was proposed to set a favorable
luminal membrane potential driving TRPM6-mediated
Mg2þ influx. Recently, Kir4.1 was postulated to enable
basolateral recirculation of Kþ , thereby supplying sufficient
Kþ necessary during high transport rates of the Naþ /Kþ -
ATPase (Figure 2). This generates the driving force for influx
of NaCl through NCC after basolateral transport of Cl
through ClC-Kb (Figure 2). The underlying mechanisms for
hypomagnesemia in patients with mutations in NCC, ClC-
Kb, or g-Naþ /Kþ -ATPase are at this point uncertain. In the
coming years, our understanding of renal Mg2þ handling
will further increase by the identification of new genes
involved in Mg2þ homeostasis, including the long-awaited
basolateral extrusion mechanism for Mg2þ . This will
ultimately facilitate the diagnosis of disturbances in Mg2þ
handling and will lead to methods to improve the
forthcoming pathophysiological conditions.
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